Sunday, August 23, 2026

UnitedHealthcare was removed from the network of a significant Medicare Consumer Operated and Oriented Plan after CMS levied a $23.5 million fine. This abrupt network change directly impacts providers credentialed with UHC who see patients from this CO-OP. For practices with patients enrolled in this specific CO-OP, claims submitted to UHC for those patients will no longer be paid. Staff must immediately verify the payer on file for all CO-OP patients and be prepared to collect out-of-network rates or direct patients to in-network alternatives. The fine and network expulsion highlight ongoing CMS scrutiny of payer compliance, which can trigger sudden, disruptive network changes.

Key provisions of the Medicare Prescription Drug Price Negotiation Program lock in on January 1, 2027. Changes include a hard out-of-pocket cap for Part D beneficiaries and new incentives for plans to prefer negotiated drugs on formulary tiers. Practices should review their Medicare patient panels for those on high-cost specialty medications; expect increased prior authorization scrutiny for non-preferred agents as plans realign. Update patient financial counseling scripts by December to explain the new cap and potential tier shifts.

The Health Resources and Services Administration revised its 340B Rebate Model Pilot Program for 2027. This program allows certain Medicaid managed care organizations to access 340B pricing. The changes could affect reimbursement rates and contracting terms for practices serving Medicaid managed care patients, particularly those associated with FQHCs or disproportionate share hospitals. The details of the revisions will shape 2027 contract negotiations. Practices should monitor updates from their state Medicaid agencies and managed care plans regarding participation and reimbursement changes tied to the pilot.

State and federal programs are using AI to streamline Medicaid applications and identify eligible but unenrolled individuals. While early pilots show increased sign-up rates, concerns about algorithmic bias, data privacy, and oversight of third-party vendors are emerging. The shift marks a significant operational change for eligibility determination, moving from manual outreach to predictive targeting. Billing teams should monitor state Medicaid agency bulletins for new enrollment pathways that could affect patient mix and payer reimbursement timelines.

AI revenue cycle management vendor Adonis named its first Chief Product Officer and Chief Revenue Officer. The move signals a broader industry shift from running one-off pilot projects to building scalable platform operating models. This consolidation phase means practices evaluating AI tools for coding, denials, or prior authorization should expect more mature, integrated products but also more vendor consolidation and stricter due diligence requirements. Early-adopter contracts from 2024-2025 may not transfer to new platform versions. The shift indicates the AI RCM market is maturing, moving from proof-of-concept to enterprise-grade solutions that require deeper integration with existing practice management and EHR systems.